News coverage about NeoGenomics (NASDAQ:NEO) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NeoGenomics earned a coverage optimism score of 0.07 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.0615649973394 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- NeoGenomics (NEO) Cut to “Buy” at BidaskClub (americanbankingnews.com)
- Analyzing NeoGenomics (NEO) and Intertek Group (IKTSY) (americanbankingnews.com)
- Global Liquid Biopsy Products Market by 2023: Pathway Genomics, Qiagen, Neo Genomics Laboraories and MDxHealth (businessservices24.com)
- NeoGenomics (NEO) Upgraded to “Hold” by Zacks Investment Research (americanbankingnews.com)
- Head to Head Review: NeoGenomics (NEO) & Intertek Group (IKTSY) (americanbankingnews.com)
Several equities analysts have commented on NEO shares. Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. BidaskClub downgraded shares of NeoGenomics from a “hold” rating to a “sell” rating in a research note on Thursday, January 18th. Scotiabank set a $22.00 price target on shares of NeoGenomics and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Canaccord Genuity boosted their price target on shares of NeoGenomics from $23.00 to $24.00 in a research note on Tuesday, March 13th. Finally, CIBC set a $19.00 price target on shares of NeoGenomics and gave the stock a “neutral” rating in a research note on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $17.29.
NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Wednesday, February 21st. The medical research company reported $0.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.02. The business had revenue of $67.79 million during the quarter, compared to analysts’ expectations of $66.32 million. NeoGenomics had a negative net margin of 1.37% and a positive return on equity of 4.34%. The company’s revenue for the quarter was up 12.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.05 EPS. sell-side analysts forecast that NeoGenomics will post 0.09 earnings per share for the current fiscal year.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.